Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozurdex for DME and ERM with Vitrectomy
NCT01613716Phase 4Completed
- Sponsor
- Cleveland Clinic
- Start
- Jul 2012
- Primary completion
- Dec 2016
- Modality
- Implantable Devices, Implantable Hydrogels, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ozurdex in diabetic macular edema (DME) and epiretinal membrane (ERM), sponsored by Cleveland Clinic. Primary endpoints: Central Retinal Thickness at 3 months and Visual Acuity at 3 months. Started Jul 2012; status: completed.
02
Drugs
ozurdex
03
Conditions
diabetic macular edema (DME)epiretinal membrane (ERM)
Beyond the preview
Go deeper on NCT01613716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01613716.